What do you all make of today's news from Victoria Gordon, which included the following: """ Dr Victoria Gordon, Managing Director and CEO of QBiotics, said “IND approval for our Soft Tissue Sarcoma trial is an important milestone for QBiotics. It is QBiotics’ first FDA IND and the culmination of a very SIGNIFICANT body of work by our team. IND approval is underpinned by a ROBUST data package, including data from our first-in-human QBC46-H01 Phase I study, where tigilanol tiglate DEMONSTRATED CLINICALLY RELEVANT monotherapy activity in 22 patients with a broad range of refractory solid tumours3.”
